ANIX insider Amit Kumar adds 5k shares, stake now 574,925

Rhea-AI Filing Summary

Form 4 filing overview: On 07/11/2025, Anixa Biosciences (ANIX) Chief Executive Officer Amit Kumar executed an open-market purchase (Code “P”) of 5,000 common shares at $3.15 per share, an aggregate value of roughly $15,750.

Following the transaction, Kumar’s direct ownership increased to 574,925 shares. No derivative securities were reported and the filing was submitted as a single-person report on 07/14/2025.

The purchase represents a ~0.9% increment to Kumar’s previously held position and signals a modest vote of confidence from the company’s most senior executive. However, given the limited dollar amount relative to both his existing stake and the company’s overall share count, the transaction is unlikely to be viewed as a materially game-changing event by the market.

Positive

• CEO insider purchase: Direct open-market buy demonstrates personal confidence in ANIX’s prospects.
• Alignment with shareholders: Increases insider ownership to 574,925 shares, reinforcing management-shareholder interest alignment.

Negative

• Limited scale: Only $15.8k worth of stock; represents < 1% increase to CEO’s stake, limiting market impact.

Insights

Securities Analyst

TL;DR – CEO’s 5k‐share buy is a small, mildly bullish signal; not materially impactful.

The Form 4 shows CEO Amit Kumar purchasing 5,000 ANIX shares at $3.15, taking his direct holdings to 574,925. Insider purchases by the chief executive are directionally positive because they align management with shareholders and often reflect internal confidence. That said, the dollar value (<$20k) and less-than-1% stake increase make the action modest. No 10b5-1 plan was indicated, suggesting discretionary buying. Overall, the filing is neutral-to-slightly positive—it may offer incremental sentiment support but is unlikely to move valuation or liquidity materially.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUMAR AMIT

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CA 95118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/11/2025		P		5,000	A	$3.15	574,925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amit Kumar	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ANIX shares did CEO Amit Kumar purchase?

He bought 5,000 common shares on 07/11/2025.

At what price were the shares acquired?

The shares were purchased at $3.15 per share.

What is Amit Kumar’s total direct ownership after the transaction?

His direct holdings increased to 574,925 ANIX shares.

Was the transaction made under a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the purchase was made pursuant to a Rule 10b5-1 plan.

Does this insider buy materially affect Anixa Biosciences’ outlook?

The purchase is a modest positive signal but not large enough to materially change the investment thesis.